Hierarchy Assignment Saphris

1. Leckman JF, Walker DE, Cohen DJ. Premonitory urges in Tourette’s syndrome. Am J Psychiatry. 1993;150:98–102.[PubMed]

2. Jankovic J. Tourette syndrome. Phenomenology and classification of tics. Neurol Clin. 1997;15:267–275.[PubMed]

3. Kurlan R, Como PG, Miller B, et al. The behavioral spectrum of tic disorders: a community-based study. Neurology. 2002;59:414–420.[PubMed]

4. Mansueto CS, Keuler DJ. Tic or compulsion?: it’s Tourettic OCD. Behav Modif. 2005;29:784–799.[PubMed]

5. Robertson MM. Tourette syndrome, associated conditions and the complexities of treatment. Brain. 2000;123(pt 3):425–462.[PubMed]

6. The Tourette Syndrome Classification Study Group. Definitions and classification of tic disorders. Arch Neurol. 1993;50:1013–1016.[PubMed]

7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. Washington DC: American Psychiatric Press Inc; 2000.

8. Palumbo D, Maughan A, Kurlan R. Hypothesis III. Tourette syndrome is only one of several causes of a developmental basal ganglia syndrome. Arch Neurol. 1997;54:475–483.[PubMed]

9. Singer HS. Tourette’s syndrome: from behaviour to biology. Lancet Neurol. 2005;4:149–159.[PubMed]

10. Mink JW. Basal ganglia dysfunction in Tourette’s syndrome: a new hypothesis. Pediatr Neurol. 2001;25:190–198.[PubMed]

11. Wong DF, Brasic JR, Singer HS, et al. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology. 2008;33:1239–1251.[PMC free article][PubMed]

12. Malison RT, McDougle CJ, van Dyck CH, et al. [123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette’s disorder. Am J Psychiatry. 1995;152:1359–1361.[PubMed]

13. Muller-Vahl KR, Berding G, Brucke T, et al. Dopamine transporter binding in Gilles de la Tourette syndrome. J Neurol. 2000;247:514–520.[PubMed]

14. Serra-Mestres J, Ring HA, Costa DC, et al. Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP-CIT/SPECT study. Acta Psychiatr Scand. 2004;109:140–146.[PubMed]

15. Cheon KA, Ryu YH, Namkoong K, Kim CH, Kim JJ, Lee JD. Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naive children with Tourette’s disorder. Psychiatry Res. 2004;130:85–95.[PubMed]

16. Albin RL, Koeppe RA, Bohnen NI, et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology. 2003;61:310–315.[PubMed]

17. Ruiz-Sandoval JL, Garcia-Navarro V, Chiquete E, et al. Choreoacanthocytosis in a Mexican family. Arch Neurol. 2007;64:1661–1664.[PubMed]

18. Hardie RJ, Pullon HW, Harding AE, et al. Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain. 1991;114 (pt 1A):13–49.[PubMed]

19. Scarano V, Pellecchia MT, Filla A, Barone P. Hallervorden-Spatz syndrome resembling a typical Tourette syndrome. Mov Disord. 2002;17:618–620.[PubMed]

20. Pellecchia MT, Valente EM, Cif L, et al. The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. Neurology. 2005;64:1810–1812.[PubMed]

21. Nardocci N, Rumi V, Combi ML, Angelini L, Mirabile D, Bruzzone MG. Complex tics, stereotypies, and compulsive behavior as clinical presentation of a juvenile progressive dystonia suggestive of Hallervorden-Spatz disease. Mov Disord. 1994;9:369–371.[PubMed]

22. Angelini L, Sgro V, Erba A, Merello S, Lanzi G, Nardocci N. Tourettism as clinical presentation of Huntington’s disease with onset in childhood. Ital J Neurol Sci. 1998;19:383–385.[PubMed]

23. Krauss JK, Jankovic J. Tics secondary to craniocerebral trauma. Mov Disord. 1997;12:776–782.[PubMed]

24. Pulst SM, Walshe TM, Romero JA. Carbon monoxide poisoning with features of Gilles de la Tourette’s syndrome. Arch Neurol. 1983;40:443–444.[PubMed]

25. Kwak CH, Jankovic J. Tourettism and dystonia after subcortical stroke. Mov Disord. 2002;17:821–825.[PubMed]

26. Gomis M, Puente V, Pont-Sunyer C, Oliveras C, Roquer J. Adult onset simple phonic tic after caudate stroke. Mov Disord. 2008;23:765–766.[PubMed]

27. Riedel M, Straube A, Schwarz MJ, Wilske B, Muller N. Lyme disease presenting as Tourette’s syndrome. Lancet. 1998;351:418–419.[PubMed]

28. Northam RS, Singer HS. Postencephalitic acquired Tourette-like syndrome in a child. Neurology. 1991;41:592–593.[PubMed]

29. Dale RC, Church AJ, Heyman I. Striatal encephalitis after varicella zoster infection complicated by Tourettism. Mov Disord. 2003;18:1554–1556.[PubMed]

30. Martino D, Chew NK, Mir P, Edwards MJ, Quinn NP, Bhatia KP. Atypical movement disorders in antiphospholipid syndrome. Mov Disord. 2006;21:944–949.[PubMed]

31. Moore DP. Neuropsychiatric aspects of Sydenham’s chorea: a comprehensive review. J Clin Psychiatry. 1996;57:407–414.[PubMed]

32. Bharucha KJ, Sethi KD. Tardive tourettism after exposure to neuroleptic therapy. Mov Disord. 1995;10:791–793.[PubMed]

33. Polizos P, Engelhardt DM, Hoffman SP, Waizer J. Neurological consequences of psychotropic drug withdrawal in schizophrenic children. J Autism Child Schizophr. 1973;3:247–253.[PubMed]

34. Sotero de Menezes MA, Rho JM, Murphy P, Cheyette S. Lamotrigine-induced tic disorder: report of five pediatric cases. Epilepsia. 2000;41:862–867.[PubMed]

35. Lombroso CT. Lamotrigine-induced tourettism. Neurology. 1999;52:1191–1194.[PubMed]

36. Neglia JP, Glaze DG, Zion TE. Tics and vocalizations in children treated with carbamazepine. Pediatrics. 1984;73:841–844.[PubMed]

37. Kurlan R, Kersun J, Behr J, et al. Carbamazepine-induced tics. Clin Neuropharmacol. 1989;12:298–302.[PubMed]

38. Pascual-Leone A, Dhuna A. Cocaine-associated multifocal tics. Neurology. 1990;40:999–1000.[PubMed]

39. Cardoso FE, Jankovic J. Cocaine-related movement disorders. Mov Disord. 1993;8:175–178.[PubMed]

40. Daniels J, Baker DG, Norman AB. Cocaine-induced tics in untreated Tourette’s syndrome. Am J Psychiatry. 1996;153:965.[PubMed]

41. Davis RE, Osorio I. Childhood caffeine tic syndrome. Pediatrics. 1998;101:E4.[PubMed]

42. Denckla MB, Bemporad JR, MacKay MC. Tics following methylphenidate administration. A report of 20 cases. JAMA. 1976;235:1349–1351.[PubMed]

43. Lowe TL, Cohen DJ, Detlor J, Kremenitzer MW, Shaywitz BA. Stimulant medications precipitate Tourette’s syndrome. JAMA. 1982;247:1729–1731.[PubMed]

44. Edwards MJ, Dale RC, Church AJ, et al. Adult-onset tic disorder, motor stereotypies, and behavioural disturbance associated with antibasal ganglia antibodies. Mov Disord. 2004;19:1190–1196.[PubMed]

45. Eapen V, Lees AJ, Lakke JP, Trimble MR, Robertson MM. Adult-onset tic disorders. Mov Disord. 2002;17:735–740.[PubMed]

46. Chouinard S, Ford B. Adult onset tic disorders. J Neurol Neurosurg Psychiatry. 2000;68:738–743.[PMC free article][PubMed]

47. Tourette’s Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58:527–536.[PubMed]

48. King A, Harris P, Fritzell J, Kurlan R. Syncope in children with Tourette’s syndrome treated with guanfacine. Mov Disord. 2006;21:419–420.[PubMed]

49. De Hert M, Schreurs V, Sweers K, et al. Typical and atypical anti-psychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008;101:295–303.[PubMed]

50. Gilbert DL, Batterson JR, Sethuraman G, Sallee FR. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry. 2004;43:206–214.[PubMed]

51. Onofrj M, Paci C, D’Andreamatteo G, Toma L. Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide. J Neurol. 2000;247:443–446.[PubMed]

52. Ben Djebara M, Worbe Y, Schupbach M, Hartmann A. Aripiprazole: a treatment for severe coprolalia in “refractory” Gilles de la Tourette syndrome. Mov Disord. 2008;23:438–440.[PubMed]

53. Yoo HK, Choi SH, Park S, Wang HR, Hong JP, Kim CY. An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. J Clin Psychiatry. 2007;68:1088–1093.[PubMed]

54. Davies L, Stern JS, Agrawal N, Robertson MM. A case series of patients with Tourette’s syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol. 2006;21:447–453.[PubMed]

55. Steingard RJ, Goldberg M, Lee D, DeMaso DR. Adjunctive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD. J Am Acad Child Adolesc Psychiatry. 1994;33:394–399.[PubMed]

56. Gonce M, Barbeau A. Seven cases of Gilles de la tourette’s syndrome: partial relief with clonazepam: a pilot study. Can J Neurol Sci. 1977;4:279–283.[PubMed]

57. Troung DD, Bressman S, Shale H, Fahn S. Clonazepam, haloperidol, and clonidine in tic disorders. South Med J. 1988;81:1103–1105.[PubMed]

58. Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2006;6:7–17.[PubMed]

59. Jain S, Greene PE, Frucht SJ. Tetrabenazine therapy of pediatric hyperkinetic movement disorders. Mov Disord. 2006;21:1966–1972.[PubMed]

60. Petzinger GM, Bressman SB. A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment. Mov Disord. 1997;12:246–248.[PubMed]

61. Jankovic J. Botulinum toxin in the treatment of dystonic tics. Mov Disord. 1994;9:347–349.[PubMed]

62. Gironell A. [Therapeutical strategies for essential tremor] Med Clin (Barc) 2007;129:632–637.[PubMed]

63. Salloway S, Stewart CF, Israeli L, et al. Botulinum toxin for refractory vocal tics. Mov Disord. 1996;11:746–748.[PubMed]

64. Trimble MR, Whurr R, Brookes G, Robertson MM. Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. Mov Disord. 1998;13:617–619.[PubMed]

65. Scott BL, Jankovic J, Donovan DT. Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette’s syndrome. Mov Disord. 1996;11:431–433.[PubMed]

66. Marras C, Andrews D, Sime E, Lang AE. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology. 2001;56:605–610.[PubMed]

67. Gilbert DL, Sethuraman G, Sine L, Peters S, Sallee FR. Tourette’s syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology. 2000;54:1310–1315.[PubMed]

68. Gilbert DL, Dure L, Sethuraman G, Raab D, Lane J, Sallee FR. Tic reduction with pergolide in a randomized controlled trial in children. Neurology. 2003;60:606–611.[PubMed]

69. Anca MH, Giladi N, Korczyn AD. Ropinirole in Gilles de la Tourette syndrome. Neurology. 2004;62:1626–1627.[PubMed]

70. Hershey T, Black KJ, Hartlein JM, et al. Cognitive-pharmacologic functional magnetic resonance imaging in tourette syndrome: a pilot study. Biol Psychiatry. 2004;55:916–925.[PubMed]

71. Orth M, Amann B, Robertson MM, Rothwell JC. Excitability of motor cortex inhibitory circuits in Tourette syndrome before and after single dose nicotine. Brain. 2005;128:1292–1300.[PubMed]

72. Marinelli M, Rudick CN, Hu XT, White FJ. Excitability of dopamine neurons: modulation and physiological consequences. CNS Neurol Disord Drug Targets. 2006;5:79–97.


To examine rates and predictors of receiving a psychosocial service before initiating antipsychotic treatment among young people in the Medicaid program.


A retrospective new-user cohort study of 8 state Medicaid programs focused on children and adolescents 0 to 20 years, initiating antipsychotic treatment (N = 24,372). The proportion receiving a psychosocial service in the 3 months before initiating antipsychotic treatment was calculated and stratified by socio-demographic and diagnostic characteristics arranged in 9 hierarchical groups, as follows: developmental, psychotic/bipolar, disruptive, attention-deficit/hyperactivity, obsessive-compulsive, stress, major depressive, anxiety, and other disorders.


Less than one-half of youth received a psychosocial service before initiating antipsychotic treatment (48.8%). Compared to younger adolescents (12–17 years) initiating antipsychotic treatment (51.5%), corresponding younger children (0–5 years; 39.2%) and older adolescents (18–20 years; 40.1%), but not older children (6–11 years; 51.5%), were significantly less likely to have received a psychosocial service. In relation to youth diagnosed with psychotic or bipolar disorder (52.7%), those diagnosed with attention-deficit/hyperactivity (43.3%), developmental (41.4%), depressive (46.5%), or anxiety (35.6%) disorder were significantly less likely to have received a psychosocial service during the 3 months before antipsychotic initiation. By contrast, youth diagnosed with stress disorders (61.2%) were significantly more likely than those diagnosed with psychotic or bipolar disorders (52.7%) to have received a psychosocial service before starting an antipsychotic.


A majority of Medicaid-insured youth initiating antipsychotic treatment have not received a psychosocial service in the preceding 3 months. This service pattern highlights a critical gap in access to psychosocial services.

Categories: 1

0 Replies to “Hierarchy Assignment Saphris”

Leave a comment

L'indirizzo email non verrà pubblicato. I campi obbligatori sono contrassegnati *